TAXOMET: A French prospective multicentric randomized phase II study of docetaxel plus metformin versus docetaxel plus placebo in metastatic castration-resistant prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TAXOMET: A French prospective multicentric randomized phase II study of docetaxel plus metformin versus docetaxel plus placebo in metastatic castration-resistant prostate cancer
Authors
Keywords
Metformin, docetaxel, metastatic castration-resistant prostate cancer, prostate cancer
Journal
Clinical Genitourinary Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-09-17
DOI
10.1016/j.clgc.2021.08.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)
- (2021) Reham Alghandour et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- European cancer mortality predictions for the year 2020 with a focus on prostate cancer
- (2020) G. Carioli et al. ANNALS OF ONCOLOGY
- Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy
- (2018) Kyle A. Richards et al. JOURNAL OF UROLOGY
- The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer
- (2017) Michelle J. Mayer et al. JOURNAL OF UROLOGY
- Metformin and Prostate Cancer: a New Role for an Old Drug
- (2017) Jessica Whitburn et al. Current Urology Reports
- Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2
- (2016) K M Biernacka et al. ENDOCRINE-RELATED CANCER
- Metformin and prostate cancer mortality: a meta-analysis
- (2015) Konrad H. Stopsack et al. CANCER CAUSES & CONTROL
- Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
- (2015) Nicholas David James et al. EUROPEAN UROLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)
- (2014) Christian Rothermundt et al. EUROPEAN UROLOGY
- Inhibition of the GTPase Rac1 Mediates the Antimigratory Effects of Metformin in Prostate Cancer Cells
- (2014) B. Dirat et al. MOLECULAR CANCER THERAPEUTICS
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences
- (2013) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality
- (2012) Daniel E. Spratt et al. EUROPEAN UROLOGY
- Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
- (2012) Bernardo Bonanni et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer
- (2012) A J Colquhoun et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Metformin in prostate cancer: two for the price of one
- (2011) A. Clements et al. ANNALS OF ONCOLOGY
- Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes
- (2011) Ben-Xu Tan et al. CANCER
- Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells
- (2011) A. A. Lubik et al. CANCER RESEARCH
- Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
- (2010) M. Pollak Cancer Prevention Research
- Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells
- (2010) I. Ben Sahra et al. CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16
- (2009) G. W.D. Landman et al. DIABETES CARE
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
- (2009) Sao Jiralerspong et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
- (2008) I Ben Sahra et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now